Danish drug giant found to have failed to accurately report spending even after admitting to errors
The pharmaceutical watchdog has reprimanded Wegovy maker Novo Nordisk for failing to correctly disclose dozens of payments to the UK health sector as it sought to boost sales of its slimming drugs.
The Danish drug giant – Europe’s most valuable listed company – systematically misreported, under-reported or did not disclose funding given over seven years to pharmacy firms, obesity charities, training providers, professional bodies and patient groups.
About Author
More Stories
Bees face new threats from wars, street lights and microplastics, scientists warn
Bankrupt DNA testing firm 23andMe to be purchased for $256m
Sea level rise will cause ‘catastrophic inland migration’, scientists warn